ArticleHistopathology2026
Endometrial carcinoma and immune escape: prognostic relevance of HLA class I loss in NSMP subtype.
Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dedifferentiation in endometrial cancer is associated with HLA-I silencing that may be restored by IFN-γ.The Journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
aimsThis study aims to define and characterize human leukocyte antigen class I (HLA-I) expression in a consecutive series of molecularly classified endometrial carcinomas (ECs), and to evaluate its association with clinicopathologic features, spatial cancer-immune phenotypes and patient prognosis, with a focus on the NSMP (no specific molecular profile) subtype. METHODS AND
resultsHLA-I expression was assessed by immunohistochemistry on whole tissue sections from 208 ECs, classified into POLE-mutated, MMR-deficient (MMRd), p53-abnormal (p53abn) and NSMP subtypes. Loss of HLA-I was identified in 31% of cases and was associated with adverse features including high-grade, aggressive histotypes, deep myometrial invasion, substantial lymphovascular space invasion (LVSI), extensive tumour necrosis and an 'excluded' immune phenotype. While HLA-I loss showed no significant prognostic impact in POLE, MMRd or p53abn tumours, it significantly correlated with worse disease-free survival in NSMP tumours (P < 0.001). Multivariate analysis confirmed HLA-I loss as an independent prognostic factor in early-stage NSMP ECs, in addition to substantial LVSI, presence of lymph node metastases and spatial cancer-immune phenotypes. Integration of HLA-I status improved the performance of predictive models over time.
conclusionsHLA-I loss defines a biologically aggressive subgroup within NSMP ECs and is associated with adverse clinicopathologic and immune features. Assessment of HLA-I expression could refine risk stratification in NSMP ECs, a group traditionally lacking robust prognostic markers and may help identify patients who could benefit from intensified clinical surveillance and future immunomodulatory treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.